Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epratuzumab dose- and regimen-ranging study in active systemic lupus erythematosus
2007-002566-35Phase 2Completed
- Sponsor
- UCB
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Epratuzumab arm with Placebo arm (2 arms). Primary endpoint: Responder rate at week 12 according to a combined response index. Started Nov 2007; status: completed.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2007-002566-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002566-35.